Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer

Authors: Mao Ouyang, Hua Wang, Jieyi Ma, Weiming Lü, Jie Li, Chen Yao, Guangqi Chang, Jiong Bi, Shenming Wang, Wenjian Wang

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

ETS variant 1 (ETV1) and E3 ubiquitin ligase constitutive photomorphogenetic 1 (COP1) have been proposed to be a pair of oncogene and tumor suppressor. However, the co-existing status of ETV1 and COP1 in triple-negative breast cancer (TNBC) and their predictive role in determining the patient’s outcome are uncertain.

Methods

We examined the abundance of COP1 and ETV1 proteins and their clinicopathologic significance in archival TNBC tissues from 105 patients by tissue microarray. The potential function link between COP1 and ETV1 was observed in MDA-MB-231 cells by cell proliferation, invasion and migration assays.

Results

ETV1 expression was higher in TNBC tissues compared to normal tissues, while COP1 was lower. ETV1 expression was negatively associated with COP1 abundance in TNBCs. Overexpression of COP1 led to significant reduction of ETV1 in MDA-MB-231 cells, and suppressed the cells migration and invasion. Rescue of ETV1 expression in the presence of COP1 notably regained the cells behaviors. ETV1-positive group was associated with a markedly poor overall survival. Meanwhile, we had observed favourable prognosis in COP1-positive cases for the first time. Multivariate analysis showed that COP1 together with ETV1 were independent risk factors in the prognosis of TNBC patients.

Conclusions

COP1 might be a tumor suppressor by negative regulating ETV1 in patients with TNBCs. COP1 and ETV1 are a pair of independent predictors of prognosis for TNBC cases. Thus, targeting them might be a potential strategy for personalized TNBC treatment.
Appendix
Available only for authorised users
Literature
1.
Maegawa ROB, Tang S-C. Triple-negative breast cancer: unique biology and its management. Cancer Investig. 2010;28:878–83.CrossRef
2.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.CrossRefPubMed
3.
Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16 suppl 1:1–11.CrossRefPubMed
4.
Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17(3):173–6.PubMed
5.
Podo F, Buydens LMC, Degani H, Hilhorst R, Klipp E, Gribbestad IS. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:209–29.CrossRefPubMed
6.
Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76.CrossRefPubMed
7.
Oh S, Shin S, Janknecht R. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta. 1826;2012:1–12.
8.
Brown TA, McKnight SL. Specificities of protein–protein and protein–DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev. 1992;6:2502–12.CrossRefPubMed
9.
Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229–34.PubMed
10.
Jané-Valbuena J, Widlund HR, Perner S, Johnson LA, Dibner AC, Lin WM, et al. An oncogenic role for ETV1 in melanoma. Cancer Res. 2010;70(5):2075–84.CrossRefPubMedPubMedCentral
11.
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.CrossRefPubMed
12.
Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467:849–55.CrossRefPubMedPubMedCentral
13.
Wang Y, Wang L, Chen Y, Li L, Yang X, Li B, et al. ER81 expression in breast cancers and hyperplasia. Patholog Res Int. 2011;2011:980513–8.PubMedPubMedCentral
14.
Yun Z, Dai T, Wang S, Peng R, Li X, Qin T, et al. Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis. OncoTargets Ther. 2014;7:1733–42.CrossRef
15.
Dowdy SC, Mariani A, Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem. 2003;278:44377–84.CrossRefPubMed
16.
Papoutsopoulou S, Janknecht R. Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol. 2000;20(19):7300–10.CrossRefPubMedPubMedCentral
17.
18.
Vitari A, Leong KG, Newton K, Yee C, O’Rourke K, Liu J, et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 2011;474:403–8.CrossRefPubMed
19.
Migliorini D, Bogaerts S, Defever D, Vyas R, Denecker G, Radaelli E, et al. Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. J Clin Invest. 2011;121(4):1329–43.CrossRefPubMedPubMedCentral
20.
Shao J, Teng Y, Padia R, Hong S, Noh H, Xie X, et al. COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia. 2013;15(9):1075–85.CrossRefPubMedPubMedCentral
21.
Wei W, Kaelin Jr WG. Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 2011;121(4):1–3.CrossRef
22.
Baert JL, Monte D, Verreman K, Degerny C, Coutte L, de Launoit Y. The E3 ubiquitin ligase complex component COP1 regulates PEA3 group member stability and transcriptional activity. Oncogene. 2010;29:1810–20.CrossRefPubMed
23.
Zurrida S, Veronesi U. A new TNM classification for breast cancer to meet the demands of he present and the challenges of the future. Women's Health. 2011;7(1):41–9.CrossRefPubMed
24.
Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res. 2007;13:4154–63.CrossRefPubMed
25.
Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, et al. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res. 2008;14:7050–9.CrossRefPubMed
26.
Baert J-L, Monte D, Musgrove EA, Albagli O, Sutherland RL, Launoit Y. Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer. 1997;70:590–7.CrossRefPubMed
27.
Trimble MS, Xin JH, Guy CT, Muller WJ, Hassell JA. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas. Oncogene. 1993;8(11):3037–42.PubMed
28.
Shin S, Bosc DG, Ingle JN, Spelsberg TC, Janknecht R. Rcl is a novel ETV1/ER81 target gene upregulated in breast tumors. J Cell Biochem. 2008;105:866–74.CrossRefPubMed
29.
Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99–110.CrossRefPubMed
30.
Wertz IE, O’Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, et al. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science. 2004;303(5662):1371–4.CrossRefPubMed
31.
Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004;64:7226–30.CrossRefPubMed
32.
Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004;429:86–92.CrossRefPubMed
Metadata
Title
COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
Authors
Mao Ouyang
Hua Wang
Jieyi Ma
Weiming Lü
Jie Li
Chen Yao
Guangqi Chang
Jiong Bi
Shenming Wang
Wenjian Wang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1151-y

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation

Research article

Influences of cancer symptom knowledge, beliefs and barriers on cancer symptom presentation in relation to socioeconomic deprivation: a systematic review

Research article

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression

Research article

Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling

Research article

Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes

Research article

Occupational exposure and sinonasal cancer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits